Undertaking Nursing Interventions Throughout Europe: Research Activities of the Working Group on Cardiovascular Nursing of the European Society of Cardiology

2002 ◽  
Vol 1 (3) ◽  
pp. 167-169 ◽  
Author(s):  
Keyword(s):  
Cardiac Disease ◽  
International Research ◽  
Working Group ◽  
Nursing Profession ◽  
Nursing Interventions ◽  
Coronary Risk Factors ◽  
Research Activities ◽  
International Collaborations ◽  
European Society Of Cardiology ◽  
Cardiovascular Nursing

The working Group on Cardiovascular Nursing is actively involved in international research though the UNITE (Undertaking Nursing Research Throughout Europe) research program, a new initiative for the WGCN. A group of cardiovascular nursing researchers from a number of different European countries committed themselves to a research group that is designed to promulgate international research in the field of cardiac nursing. The first study was a survey on coronary risk factors in a cohort of cardiac nurses from Europe. At this moment four additional studies are planned aimed at the development of the nursing profession in Europe and improvement of care for patients with chronic cardiac disease. If, as hoped, these studies prove to be successful, it will provide the seed for other international collaborations of this type.

scholarly journals Extracellular vesicles in diagnostics and therapy of the ischaemic heart: Position Paper from the Working Group on Cellular Biology of the Heart of the European Society of Cardiology

2017 ◽  
Vol 114 (1) ◽  
pp. 19-34 ◽  
Author(s):  
Joost Petrus Gerardus Sluijter ◽  
Sean Michael Davidson ◽  
Chantal M Boulanger ◽  
Edit Iren Buzás ◽  
Dominique Paschalis Victor de Kleijn ◽  
...  
Keyword(s):  
Extracellular Vesicles ◽  
Working Group ◽  
Position Paper ◽  
Paracrine Effects ◽  
Group Position ◽  
Wide Range ◽  
Potential Alternative ◽  
Number Of Publications ◽  
European Society Of Cardiology ◽  
Regenerative Therapies

AbstractExtracellular vesicles (EVs)—particularly exosomes and microvesicles (MVs)—are attracting considerable interest in the cardiovascular field as the wide range of their functions is recognized. These capabilities include transporting regulatory molecules including different RNA species, lipids, and proteins through the extracellular space including blood and delivering these cargos to recipient cells to modify cellular activity. EVs powerfully stimulate angiogenesis, and can protect the heart against myocardial infarction. They also appear to mediate some of the paracrine effects of cells, and have therefore been proposed as a potential alternative to cell-based regenerative therapies. Moreover, EVs of different sources may be useful biomarkers of cardiovascular disease identities. However, the methods used for the detection and isolation of EVs have several limitations and vary widely between studies, leading to uncertainties regarding the exact population of EVs studied and how to interpret the data. The number of publications in the exosome and MV field has been increasing exponentially in recent years and, therefore, in this ESC Working Group Position Paper, the overall objective is to provide a set of recommendations for the analysis and translational application of EVs focussing on the diagnosis and therapy of the ischaemic heart. This should help to ensure that the data from emerging studies are robust and repeatable, and optimize the pathway towards the diagnostic and therapeutic use of EVs in clinical studies for patient benefit.

scholarly journals Antithrombotic Therapy in Atrial Fibrillation Associated with Valvular Heart Disease: Executive Summary of a Joint Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE)

2017 ◽  
Vol 117 (12) ◽  
pp. 2215-2236 ◽  
Author(s):  
Gregory Lip ◽  
Jean Collet ◽  
Raffaele de Caterina ◽  
Laurent Fauchier ◽  
Deirdre Lane ◽  
...  
Keyword(s):  
Heart Disease ◽  
South African ◽  
Valvular Heart Disease ◽  
Working Group ◽  
Heart Association ◽  
Heart Rhythm ◽  
Asia Pacific ◽  
Executive Summary ◽  
Consensus Document ◽  
European Society Of Cardiology

AbstractManagement strategies for patients with atrial fibrillation (AF) in association with valvular heart disease (VHD) have been less informed by randomized trials, which have largely focused on ‘non-valvular AF’ patients. Thromboembolic risk also varies according to valve lesion and may also be associated with CHA2DS2-VASc score risk factor components, rather than only the valve disease being causal.Given the need to provide expert recommendations for professionals participating in the care of patients presenting with AF and associated VHD, a task force was convened by the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group (WG) on Thrombosis, with representation from the ESC WG on Valvular Heart Disease, Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE) with the remit to comprehensively review the published evidence, and to produce a consensus document on the management of patients with AF and associated VHD, with up-to-date consensus statements for clinical practice for different forms of VHD, based on the principles of evidence-based medicine.This is an executive summary of a consensus document which proposes that the term ‘valvular AF’ is outdated and given that any definition ultimately relates to the evaluated practical use of oral anticoagulation (OAC) type, we propose a functional EHRA (Evaluated Heartvalves, Rheumatic or Artificial) categorization in relation to the type of OAC use in patients with AF, as follows: (1) EHRA (Evaluated Heartvalves, Rheumatic or Artificial) type 1 VHD, which refers to AF patients with ‘VHD needing therapy with a vitamin K antagonist (VKA)’ and (2) EHRA (Evaluated Heartvalves, Rheumatic or Artificial) type 2 VHD, which refers to AF patients with ‘VHD needing therapy with a VKA or a non-VKA oral anticoagulant also taking into consideration CHA2DS2-VASc score risk factor components.

Sign in / Sign up

Export Citation Format

Share Document